11. Results from the primary analysis of a 30 patient extension of the GATTO study, a phase Ib study combining the anti-MUC1 Gatipotuzumab (GAT) with the anti-EGFR Tomuzotuximab (TO) or Panitumumab in patients with refractory solid tumors. (October 2020) Authors: Macchini, M.; Garralda, E.; Fiedler, W.; Del Conte, G.; Rolling, C.; Kebenko, M.; Klinghammer, K.F.; Ahrens-fath, I.; Habel, B.; Baumeister, H.; Zurlo, A.; Ochsenreiter, S. Journal: European journal of cancer Issue: Volume 138(2020)Supplement 2 Page Start: S5 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
12. Transition to the new EU CTIS Portal for Regulatory Clinical Trial Submissions: VHIO's Start-Up Unit Analysis. (October 2022) Authors: Matres, A.; Carballo, N.; Bernabé, Y.; Martínez, A.; Silverio, A.; Depares, I.; Cidoncha, I.; Beltran, M.; Braña, I.; Élez, E.; Díez, M.; Muñoz, E.; Saura, C.; Oaknin, A.; Macarulla, T.; Carles, J.; Felip, E.; Tabernero, J.; Garralda, E.; Pérez-Pujol, S. Journal: European journal of cancer Issue: Volume 174(2022)Supplement 1 Page Start: S48 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗